Thursday, 2 December 2021

Australia's most trusted
source of pharma news

Thursday, 02 December 2021

Keytruda could boost economy

Posted 22 November 2021 AM

A new report, commissioned by MSD, projects the potential that anti PD-1/PD-L1 inhibitors could have beyond improving survival, if used in all eligible Australian cancer patients.

The Health Impact Projection (HIP) 2.0 analysis, which estimated the benefit derived from helping patients stay in the workplace, stay out of hospital and contribute to their communities and the economy, highlights the importance of policy work to provide faster access to these cancer treatments.

To see the whole article, please login

Email this article to a friend

Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.


Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.


Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).


You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.


You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.